Comparison of the Results of Bronchoalveolar Lavage Culture and Endotracheal Aspirate Culture in Intubated Critically Ill COVID-19 Patients

Critical Illness Clinical Trial

Official title:

Comparison of the Results of Bronchoalveolar Lavage Culture and Endotracheal Aspirate Culture in Intubated Critically Ill COVID-19 Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05403489
• Other study ID #: HisarIH
• Status: Completed
• Start date: January 1, 2021
• Est. completion date: May 31, 2022

Study information

• Verified date: June 2022
• Source: Hisar Intercontinental Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Introduction: Secondary pneumonia is frequently seen in COVID-19 cases followed up intubated, and high mortality rates can be observed. Isolation of the agent with bronchoalveolar lavage (BAL) culture or endotracheal aspirate (ETA) culture may increase the success of treatment. This study aimed to retrospectively analyze the results of BAL and ETA cultures in intubated COVID-19 cases. Methods: We routinely apply BAL culture with bronchoscopy or ETA culture within the first 48 hours after intubating. We retrospectively screened cases who underwent BAL and ETA. They were divided into two groups: Group B and E. Evaluated parameters were compared in both groups. Results: Demographic data and blood test results were similar in both groups. Intensive care unit (ICU) and intubation durations, and culture positivity were statistically significantly higher in Group B. Although not statistically significant, the mortality rate was higher in Group E. The most growth microorganisms were Candida species. Conclusion: Mortality rates were consistent with the literature. Since the microorganism isolation rate is higher with BAL and antimicrobial treatment is applied more effectively; early deaths were prevented and stay periods were prolonged. In contrast, these durations were shorter in the ETA group due to higher mortality. In intubated COVID-19 cases, a more effective treatment process can be carried out by clearing the airway with fiberoptic bronchoscopy and by specifically planning the treatment according to the BAL culture. This may have a positive effect on prognosis and mortality.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: May 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Intubated COVID-19 patients
• Above 18 years old patients

Exclusion Criteria:

• Non COVID-19 patients
• Non intubated COVID-19 patients
• Below 18 years old patients

Related Conditions & MeSH terms

• Bronchoalveolar Lavage
• COVID-19
• COVID-19 Pneumonia
• Critical Illness

Intervention

Procedure:
• Bronchoalveolar lavage
In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
• endotracheal aspirate culture
In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.

Locations

Country	Name	City	State
Turkey	Hisar Intercontinental Hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Basri Cakiroglu

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Culture positivity	Significantly higher microbiological culture growth rate was obtained in Group B	1 years
Primary	Length of stay in intensive care unit	Significantly higher duration of stay in intensive care unit was found in Group B	1 years
Primary	Duration of intubation	Significantly higher duration of stay intubated was observed in Group B	1 years
Primary	Mortality	Mortality rate was higher in Group E. But not statistically significant.	1 years
Secondary	Microorganism	The most growing microorganism in both groups was the Candida species.	1 years